Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
Rigel Medical
Primedic

New Injection Device Approved for Methotrexate

By HospiMedica International staff writers
Posted on 31 Oct 2013
Image: The Otrexup self-injector in 10 mg formulation (Photo courtesy of Antares Pharma).
Image: The Otrexup self-injector in 10 mg formulation (Photo courtesy of Antares Pharma).
A self-injection device for the subcutaneous administration of methotrexate (MTX) facilitates drug delivery for arthritis sufferers.

The Otrexup self-injector is intended for use by adults with active, severe rheumatoid arthritis (RA) or psoriasis who have not responded to or been able to tolerate first line therapy, as well as for children with active polyarticular juvenile idiopathic arthritis. The device is not indicated for use in children with psoriasis, nor should it be used by pregnant women. And while MTX is also used in the treatment of cancer, Otrexup is not indicated for that use.

Methotrexate is considered a disease-modifying antirheumatic drug (DMARD), effective in relieving joint inflammation and pain, slowing disease progression, and preventing disability by delaying joint destruction. People with RA may be more likely to continue treatment with MTX than with other DMARDs, with more than 50% of people who take MTX for RA continuing to take the medicine for more than three years, longer than any other DMARD. The Otrexup self-injector is a product of Antares Pharma (Ewing, NJ, USA), and has been approved by the US Food and Drug Administration (FDA).

“We are very pleased to receive approval from the FDA for Otrexup because we believe it is an important step up in the standard of care for people living with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis,” said Paul Wotton, PhD, president and CEO of Antares Pharma.

“The availability of an easy and safe way to administer subcutaneous methotrexate may overcome some of the current barriers to parenteral administration, which could enable more patients to realize the possibility of continued disease control and therefore benefit from subcutaneous methotrexate,” commented Michael Schiff, MD, of the University of Colorado (Denver, USA).

MTX is a cornerstone of therapy for RA and psoriasis, usually given orally once a week, but a substantial number of patients do not respond adequately or cannot tolerate the side effects of the drug, such as nausea, abdominal pain, and dyspepsia. Those patients can be given methotrexate with subcutaneous injections, which can increase the drug's bioavailability, but injection can also pose problems for patients who are afraid of needles or do not have enough manual dexterity remaining to manage needles, syringes, and vials.

Related Links:

Antares Pharma



Channels

Women's Health

view channel

Tampons Could Help Predict Endometrial Cancer

A new study shows that vaginal secretions in tampons can be used to detect the presence of endometrial cancer DNA. Researchers at the Mayo Clinic (Rochester, MN, USA) obtained samples from 66 women who were about to undergo a hysterectomy, 38 of them due to endometrial cancer and 28 due to other indications.... Read more

Hospital News

view channel

Ventas to Buy Healthcare Services Provider Ardent

Healthcare real-estate investment trust (REIT) Ventas (Chicago, IL, USA) will buy hospital operator Ardent Medical Services (Nashville, TN, USA) for USD 1.75 billion in cash. Under the terms of the agreement, Ventas will own 10 hospital properties and will separate their operations into entities that will be owned by... Read more

Business

view channel
Image: Entrance to Medical Fair India 2015 (Photo courtesy of Boson Biotech).

Booming Health Market Benefits Medical Fair India

Over 10,400 international trade visitors attended Medical Fair India 2015, India’s premier trade fair for hospitals, health centers, and clinics. The 21st International Exhibition and Conference held... Read more
 

Events

27 Apr 2015 - 29 Apr 2015
28 Apr 2015 - 01 May 2015
05 May 2015 - 07 May 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.